Jonathan Burress, DO
Cardiovascular Disease · Bristol, TNNPI 1760415582
Payments from drug & device makers
Across 573 payments — averaging $75.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$34K
- Abbott$3K
- Novartis$2K
- Medtronic$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$818
- Amgen$342
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$33,62078%
- Travel & lodging$2020%
- Food & beverage$9,40022%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 43 | $34,178 |
| Abbott | 108 | $2,592 |
| Novartis | 124 | $2,064 |
| Medtronic(2 entities) | 58 | $1,038 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 87 | $818 |
| Amgen | 19 | $342 |
| Daiichi Sankyo Inc. | 11 | $252 |
| AstraZeneca | 19 | $246 |
| Boehringer Ingelheim | 13 | $213 |
| E.r. Squibb & Sons, L.L.C. | 18 | $201 |
| Johnson & Johnson | 18 | $197 |
| Boston Scientific | 8 | $189 |
| Pfizer | 10 | $160 |
| Atricure, Inc. | 2 | $77 |
| Actelion Pharmaceuticals US, Inc. | 2 | $57 |
| Lexicon Pharmaceuticals, Inc. | 3 | $55 |
| Cardiovascular Systems Inc. | 4 | $53 |
| Irhythm Technologies, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 3 | $52 |
| Merck | 3 | $50 |
| Stryker | 1 | $44 |
| Inari Medical, Inc. | 1 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Philips North America LLC | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Abiomed | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Convatec Inc. | 1 | $20 |
| Elutia, Inc. | 1 | $18 |
| Cook Medical LLC | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $11 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$33,620
- NEXLETOL$33,620
- MitraClip$148
- AMPLATZER TALISMAN$106
- Micra$104
How this compares
$43,222 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 504 | $399,384 |
| EntrestoSacubitril/Valsartan | 158 | $118,322 |
| XareltoRivaroxaban | 149 | $94,643 |
| BrilintaTicagrelor | 51 | $35,334 |
| NexlizetBempedoic Acid/Ezetimibe | 48 | $27,073 |
| Repatha SureclickEvolocumab | 22 | $18,501 |
| JardianceEmpagliflozin | 16 | $14,332 |
| Ranolazine ErRanolazine | 97 | $9,228 |
| NexletolBempedoic Acid | 19 | $8,702 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 126 | $2,416 |
| Rosuvastatin Calcium | 199 | $2,112 |
| Atorvastatin Calcium | 210 | $1,817 |
| Metoprolol Tartrate | 309 | $1,608 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 163 | $1,428 |
| Metoprolol Succinate | 131 | $1,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $160 | $399,384504 claims |
| NovartisEntresto | $2,064 | $118,322158 claims |
| Johnson & JohnsonXarelto | $197 | $94,643149 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $34,178 | $35,77567 claims |
| AstraZenecaBrilinta | $246 | $35,33451 claims |
| Boehringer IngelheimJardiance | $213 | $14,33216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Bristol
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
- Joann LindenfeldNashville$2.2M
- Frank McGrewMemphis$2.1M
- Rebecca HungNashville$1.8M
- Mohsin AlhaddadJackson$1.8M
- Robert SmithBrentwood$1.3M
- Travis RichardsonNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.